Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01794793 · FLOW

Participant flow

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies · Source last updated 2024-10-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients who were treated with and had benefitted from pasireotide in the parent studies remained enrolled in this study and were elegible for the analysis
    id
    FG000
    title
    All Subjects
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        24
      type
      Withdrawal by Subject
    2. reasons
      1. group Id
        FG000
        num Subjects
        22
      type
      Lack of Efficacy
    3. reasons
      1. group Id
        FG000
        num Subjects
        17
      type
      Adverse Event
    4. reasons
      1. group Id
        FG000
        num Subjects
        14
      type
      Physician Decision
    5. reasons
      1. group Id
        FG000
        num Subjects
        7
      type
      Lost to Follow-up
    6. reasons
      1. group Id
        FG000
        num Subjects
        6
      type
      Death
    7. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Protocol Violation
    8. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      administrative problem
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        337
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        239
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        98
      type
      NOT COMPLETED
    title
    Treatment Period
  2. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        14
      type
      Lack of Efficacy
    2. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Adverse Event
    3. reasons
      1. group Id
        FG000
        num Subjects
        6
      type
      Withdrawal by Subject
    4. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      administrative problem
    5. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Lost to Follow-up
    6. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Protocol Violation
    milestones
    1. achievements
      1. comment
        188/ 337 patients did not enter the post-treatment follow-up safety evaluation
        group Id
        FG000
        num Subjects
        149
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        110
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        39
      type
      NOT COMPLETED
    title
    Post-treatment Follow-up
recruitment Details
No target number of patients pre-specified for this study
Complete source fields
groups
  1. description
    Patients who were treated with and had benefitted from pasireotide in the parent studies remained enrolled in this study and were elegible for the analysis
    id
    FG000
    title
    All Subjects
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        24
      type
      Withdrawal by Subject
    2. reasons
      1. group Id
        FG000
        num Subjects
        22
      type
      Lack of Efficacy
    3. reasons
      1. group Id
        FG000
        num Subjects
        17
      type
      Adverse Event
    4. reasons
      1. group Id
        FG000
        num Subjects
        14
      type
      Physician Decision
    5. reasons
      1. group Id
        FG000
        num Subjects
        7
      type
      Lost to Follow-up
    6. reasons
      1. group Id
        FG000
        num Subjects
        6
      type
      Death
    7. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Protocol Violation
    8. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      administrative problem
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        337
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        239
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        98
      type
      NOT COMPLETED
    title
    Treatment Period
  2. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        14
      type
      Lack of Efficacy
    2. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Adverse Event
    3. reasons
      1. group Id
        FG000
        num Subjects
        6
      type
      Withdrawal by Subject
    4. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      administrative problem
    5. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Lost to Follow-up
    6. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Protocol Violation
    milestones
    1. achievements
      1. comment
        188/ 337 patients did not enter the post-treatment follow-up safety evaluation
        group Id
        FG000
        num Subjects
        149
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        110
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        39
      type
      NOT COMPLETED
    title
    Post-treatment Follow-up
recruitment Details
No target number of patients pre-specified for this study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice